Oral administration of Lactobacillus brevis 23017 combined with ellagic acid attenuates intestinal inflammatory injury caused by Eimeria infection by activating the Nrf2/HO-1 antioxidant pathway

The aim of this study was to investigate whether oral administration of Lactobacillus brevis 23017 (LB) alone and in combination with ellagic acid inhibits ChTLR15/ChNLRP3/ChIL-1β by activating the Nrf2/HO-1 pathway to attenuate intestinal inflammatory injury. Two animal experiments were performed....

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xuelian, Pan, Xinghui, Jia, Zhipeng, Bai, Bingrong, Zhi, Wenjing, Chen, Hang, Ma, Chunli, Ma, Dexing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931975/
https://www.ncbi.nlm.nih.gov/pubmed/35303923
http://dx.doi.org/10.1186/s13567-022-01042-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931975/
https://www.ncbi.nlm.nih.gov/pubmed/35303923
http://dx.doi.org/10.1186/s13567-022-01042-z

Ejemplares similares